NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!
Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.
Start Free »

VCYT | NASDAQ

$46.08 $0.85 | 1.88%
SIGNAL:Signal available — unlock to view |2026-09-24 |F&G 38 |RSI 55.6

Company Overview:

Market Cap: $3.67B
Trailing PE: 32.9x
FWD PE *: 25.7x
Payout Ratio (TTM): —
52-Week Range: $29.46 - $60.91

* Forward PE is based on street estimates.

10 Year VCYT Performance Metrics:

Total Return (with DRIP): 506% (19.73% CAGR)
Total Return (no DRIP): 506% (19.73% CAGR)
Share Price: 506% (19.73% CAGR)
Yield on Cost (with DRIP): —
Total Invested: $10,000
Total Value (with DRIP): $60,552
Total Return $ (with DRIP): $50,552
VCYT Total Return
1M 3M 6M YTD 1Y 3Y 5Y 10Y
VCYT Price Chart
1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)

VCYT Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

VCYT - Revenue
VCYT Revenue CAGR:1Y: 15.49%2Y: 14.62%5Y: 22.23%10Y: 26.20%
VCYT - Earnings Per Share (EPS)
VCYT EPS CAGR:1Y: 0.00%2Y: 104.26%5Y: 0.00%10Y: 0.00%
VCYT - Net Income
🔓 See the full chart40% off right now · 7-day free trial
VCYT Net Income CAGR:1Y: 0.00%2Y: 110.84%5Y: 0.00%10Y: 0.00%
VCYT - EBITDA
🔓 See the full chart40% off right now · 7-day free trial
VCYT EBITDA CAGR:1Y: 260.31%2Y: 47.61%5Y: 0.00%10Y: 0.00%
VCYT - Free Cash Flow
🔓 See the full chart40% off right now · 7-day free trial
VCYT Free Cash Flow CAGR:1Y: 32.95%2Y: 26.61%5Y: 160.24%10Y: 0.00%
VCYT - Free Cash Flow / Share
🔓 See the full chart40% off right now · 7-day free trial
VCYT Free Cash Flow / Share CAGR:1Y: 30.53%2Y: 24.10%5Y: 151.62%10Y: 0.00%
VCYT - Operating Income
🔓 See the full chart40% off right now · 7-day free trial
VCYT Operating Income CAGR:1Y: 0.00%2Y: 121.01%5Y: 0.00%10Y: 0.00%
VCYT - Gross Profit
🔓 See the full chart40% off right now · 7-day free trial
VCYT Gross Profit CAGR:1Y: 20.93%2Y: 19.68%5Y: 23.60%10Y: 29.20%
VCYT - Shares Outstanding
🔓 See the full chart40% off right now · 7-day free trial
VCYT Shares Outstanding CAGR:1Y: 2.90%2Y: 3.23%5Y: 4.08%10Y: 11.43%
VCYT - Share Buybacks
🔓 See the full chart40% off right now · 7-day free trial
VCYT Share Buybacks CAGR:1Y: 0.00%2Y: 81.53%5Y: 43.32%10Y: 0.00%
VCYT - Stock-Based Comp
🔓 See the full chart40% off right now · 7-day free trial
VCYT Stock-Based Comp CAGR:1Y: 28.23%2Y: 19.56%5Y: 28.22%10Y: 23.72%
VCYT - Expenses
🔓 See the full chart40% off right now · 7-day free trial
VCYT Expenses CAGR:1Y: 122.32%2Y: 1.59%5Y: 13.36%10Y: 14.60%
VCYT - Revenue vs Net Income
🔓 See the full chart40% off right now · 7-day free trial
VCYT - EPS vs FCF / Share
🔓 See the full chart40% off right now · 7-day free trial
VCYT - EPS vs PE Ratio
🔓 See the full chart40% off right now · 7-day free trial
VCYT - FCF vs FCF / Share
🔓 See the full chart40% off right now · 7-day free trial
VCYT - FCF vs Stock Based Comp
🔓 See the full chart40% off right now · 7-day free trial
VCYT - Cash & Debt
🔓 See the full chart40% off right now · 7-day free trial
VCYT - Revenue by Segment
🔓 See the full chart40% off right now · 7-day free trial
VCYT Revenue CAGR:1Y: 15.49%2Y: 14.62%5Y: 22.23%10Y: 26.20%
VCYT - Revenue by Region
🔓 See the full chart40% off right now · 7-day free trial
VCYT Revenue CAGR:1Y: 15.49%2Y: 14.62%5Y: 22.23%10Y: 26.20%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

VCYT - REVENUE: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
VCYT Actual Revenue CAGR:1Y: 15.49%2Y: 14.62%5Y: 22.23%10Y: 26.20%
VCYT - EPS: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
VCYT Actual EPS CAGR:1Y: 0.00%2Y: 104.26%5Y: 0.00%10Y: 0.00%
VCYT - NET INCOME: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
VCYT Actual Net Income CAGR:1Y: 0.00%2Y: 110.84%5Y: 0.00%10Y: 0.00%
VCYT - EBITDA: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
VCYT Actual EBITDA CAGR:1Y: 260.31%2Y: 47.61%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

VCYT - Net Profit Margin
🔓 See the full chart40% off right now · 7-day free trial
VCYT Net Profit Margin CAGR:1Y: 0.00%2Y: 83.99%5Y: 0.00%10Y: 0.00%
VCYT - Gross Profit Margin
🔓 See the full chart40% off right now · 7-day free trial
VCYT Gross Profit Margin CAGR:1Y: 4.70%2Y: 4.42%5Y: 1.12%10Y: 2.38%
VCYT - Price to Earnings
🔓 See the full chart40% off right now · 7-day free trial
VCYT Price to Earnings CAGR:1Y: 0.00%2Y: -19.71%5Y: 0.00%10Y: 0.00%
VCYT - Price To Sales Ratio
🔓 See the full chart40% off right now · 7-day free trial
VCYT Price To Sales Ratio CAGR:1Y: 91.62%2Y: 47.69%5Y: -8.62%10Y: 12.54%
VCYT - Return on Capital Employed
🔓 See the full chart40% off right now · 7-day free trial
VCYT Return on Capital Employed CAGR:1Y: 0.00%2Y: 99.67%5Y: 0.00%10Y: 0.00%
VCYT - Return on Invested Capital
🔓 See the full chart40% off right now · 7-day free trial
VCYT Return on Invested Capital CAGR:1Y: 396.08%2Y: 127.16%5Y: 0.00%10Y: 0.00%

Compare stocks side-by-side

Projected Future Returns & Dividends for VCYT

Based on past 10-year performance, here are VCYT growth metrics:

Share price CAGR of +20%
Dividend CAGR of +0%

Using VCYT CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

VCYT (DRIP)VCYT - No DRIP
Current Price$46.08$46.08
Start Shares217.01217.01
Start Value$10,000$10,000
  
After 10 years:
Final Share Count217.01217.01
Dividends Payment$0.00$0.00
Annual Dividends$0$0
Yield on cost0.00%0.00%
Share Price$46.08$46.08
Total Dividends$0$0
Final Value$10,000$10,000

Estimated Future Value + Dividends - VCYT

NOTE: Above numbers are our estimate based on VCYT's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)

Company Info

Veracyte, Inc. (VCYT) had its IPO on 2013-10-29, and is traded on NASDAQ stock exchange.

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYT website: https://www.veracyte.com


Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)
Loading signals…

DCF Model — VCYT

Value from:
Pay up to today
—
vs current price $46.08
—
Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
YearFCFImplied price
Sensitivity — fair value: growth ↓ × target return →